| Name | Title | Contact Details |
|---|---|---|
Yuhong Qiu |
VP, Regulatory Affairs | Profile |
Jim Pepin |
General Counsel | Profile |
Kurome Therapeutics is developing therapies that target cancer cells that have co-opted immune signaling pathways in order to avoid destruction by traditional therapeutic agents and subvert adaptive resistance mechanisms.
JPT Peptide Technologies GmbH is a Acton, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Passage Bio was launched with the vision to be a first in class fully-integrated biotech company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. In collaboration with the University of Pennsylvania Gene Therapy Program, Philadelphia-based Passage Bio plans to advance a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using best-in-class AAV technology and know-how. Subsequently, Passage Bio will be responsible for all clinical development and will collaborate with Penn`s Orphan Disease Center to support these efforts.
Ziemer USA INC is a Wood River, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Cardiome Pharma Corp. is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.